ASLN vs. NBRV, VIRX, CARM, MBIO, HCWB, NRXP, PRAX, ASMB, BIOR, and ANEB
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Nabriva Therapeutics (NBRV), Viracta Therapeutics (VIRX), Carisma Therapeutics (CARM), Mustang Bio (MBIO), HCW Biologics (HCWB), NRx Pharmaceuticals (NRXP), Praxis Precision Medicines (PRAX), Assembly Biosciences (ASMB), Biora Therapeutics (BIOR), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "medical" sector.
ASLAN Pharmaceuticals vs.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.
Nabriva Therapeutics received 201 more outperform votes than ASLAN Pharmaceuticals when rated by MarketBeat users. However, 62.54% of users gave ASLAN Pharmaceuticals an outperform vote while only 62.38% of users gave Nabriva Therapeutics an outperform vote.
In the previous week, ASLAN Pharmaceuticals and ASLAN Pharmaceuticals both had 1 articles in the media. ASLAN Pharmaceuticals' average media sentiment score of 0.47 beat Nabriva Therapeutics' score of 0.00 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.
ASLAN Pharmaceuticals has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.
31.6% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Nabriva Therapeutics shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ASLAN Pharmaceuticals presently has a consensus price target of $16.00, indicating a potential upside of 316.67%. Given ASLAN Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ASLAN Pharmaceuticals is more favorable than Nabriva Therapeutics.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. ASLAN Pharmaceuticals' return on equity of -315.43% beat Nabriva Therapeutics' return on equity.
ASLAN Pharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ASLAN Pharmaceuticals beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
